Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
P
388870
vs
K
KOSPI 200
Over the past 12 months, Pharos IBio Co Ltd has underperformed KOSPI 200, delivering a return of 0% compared to KOSPI 200's +119% growth.
Stocks Performance
388870 vs KOSPI 200
Performance Gap
388870 vs KOSPI 200
Performance By Year
388870 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Pharos IBio Co Ltd
Glance View
Pharos iBio Co Ltd is a Korean biotechnology company that searches for new drug candidates and develops them into potential medicines, especially in cancer and other serious diseases. It does not sell consumer products; its core business is building drug programs, running preclinical and clinical development work, and advancing those programs far enough to attract partners or approvals. The company makes money mainly through collaboration deals, technology transfer, licensing, and research-related payments from pharmaceutical partners and other organizations that want access to its drug candidates or discovery know-how. In this kind of business, the value is often created long before a medicine reaches patients, so the company’s work is centered on discovery, testing, and partnering rather than mass manufacturing or retail sales. What makes Pharos iBio different is its role as a drug creator rather than a drug seller. It sits early in the pharmaceutical value chain, where success depends on finding promising molecules, proving they work, and handing them off to bigger drugmakers or taking them further through development. For investors, it is best understood as a research-driven biotech whose prospects depend on the quality of its pipeline and its ability to turn science into licensing or commercial deals.